Page last updated: 2024-08-22

betamethasone-17,21-dipropionate and fluticasone

betamethasone-17,21-dipropionate has been researched along with fluticasone in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (66.67)18.2507
2000's1 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Roberts, DT1
Delescluse, J; van der Endt, JD1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1

Trials

2 trial(s) available for betamethasone-17,21-dipropionate and fluticasone

ArticleYear
Comparison of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of psoriasis.
    Cutis, 1996, Volume: 57, Issue:2 Suppl

    Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Anti-Inflammatory Agents; Betamethasone; Double-Blind Method; Female; Fluticasone; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Psoriasis

1996
A comparison of the safety, tolerability, and efficacy of fluticasone propionate ointment, 0.005%, and betamethasone-17,21-dipropionate ointment, 0.05%, in the treatment of eczema.
    Cutis, 1996, Volume: 57, Issue:2 Suppl

    Topics: Administration, Topical; Adolescent; Adult; Aged; Androstadienes; Anti-Inflammatory Agents; Betamethasone; Child; Double-Blind Method; Drug Tolerance; Eczema; Female; Fluticasone; Humans; Hydrocortisone; Male; Middle Aged; Ointments; Safety

1996

Other Studies

1 other study(ies) available for betamethasone-17,21-dipropionate and fluticasone

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004